V.I. Technologies

Biotechnology company amends merger agreement with HIV-focused pharm firm

Published in Medicine and Law Weekly, December 10th, 2004

V.I. Technologies, Inc. (VITX), a biotechnology company that develops anti-infective technologies, has amended the terms of the merger agreement with privately held Panacos Pharmaceuticals, a biotechnology company developing antiviral drugs to treat HIV infection and other major human viral diseases.

Under the terms of the amendment, Vitex will issue approximately 54.5 million shares at closing to complete the merger and acquire all Panacos outstanding shares. Panacos shareholders will have the opportunity to receive an additional 30.5 million Vitex shares if it successfully completes Panacos Study 201, a phase 2 study in HIV-infected patients.

The...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medicine and Law Weekly

Source: Medicine and Law Weekly (2004-12-10)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry